Molecular Formula | C19H32N2O5 |
Molar Mass | 368.47 |
Density | 1.167±0.06 g/cm3(Predicted) |
Solubility | DMSO: 30mg/mL, soluble |
Appearance | solid |
Color | off-white |
pKa | 4.77±0.10(Predicted) |
Storage Condition | −20°C |
In vitro study | BW245C (0.01-1 μM) suppresses TGF-β-induced collagen secretion in a dose-dependent manner in Th2 cells. BW245C (0.01-1 μM) also increases intracellular cAMP in lung fibroblasts. BW245C (0.1-3 μmol/L) dose-dependently increases transendothelial electrical resistance and decreases the FITC-dextran permeability of human umbilical vein endothelial cells. BW245C (0.3 μmol/L) increases the intracellular cAMP level and subsequent protein kinase A (PKA) activity. |
In vivo study | BW245C (0.02, 0.2, and 2.0 mg/kg) in WT mice results in a significant increase in CBF, but this effect of this treatment is absent in DP1 −/− mice. BW245C attenuates functional deficits after stroke. BW245C significantly reverses these conditions that neurologic deficit is significantly augmented, whereas locomotor activity is significantly reduced after stroke in WT mice. BW245C (0.2 mg/kg) injection 1 h after stroke results in a significant decrease in brain infarction in WT mice, whereas the effect of this treatment is not observed in DP1 −/− mice. BW245C improves CBF during and after stroke. BW245C results in significantly prolonged bleeding compared with the vehicle-treated group. BW 245C (100 nM) does not significantly increase MBP-positive eosinophils in esophageal epithelium in OVA-sensitized guinea pigs. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.714 ml | 13.57 ml | 27.139 ml |
5 mM | 0.543 ml | 2.714 ml | 5.428 ml |
10 mM | 0.271 ml | 1.357 ml | 2.714 ml |
5 mM | 0.054 ml | 0.271 ml | 0.543 ml |
biological activity | BW 245C is a potent prostaglandin DP receptor prostanoid DP-receptor (DP1) agonist, commonly used in the study of stroke and other diseases. |